Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 18/20 | 0.63 |
| ▸ | F2 | P00734 | 4/20 | 0.63 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.62 |
| ▸ | PDE4A | P27815 | 2/20 | 0.58 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.58 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.58 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16948138 | 0.93 | F10 (0.64) | F10F2SLC29A1PDE4APDE4B | |
| SCHEMBL5307046 | 0.92 | F10 (0.67) | F10F2SLC29A1PDE4APDE4B | |
| SCHEMBL15731769 | 0.92 | F10 (0.67) | F10F2SLC29A1PDE4APDE4B | |
| SCHEMBL1995178 | 0.91 | F10 (0.62) | F10F2SLC29A1PDE4APDE4B | |
| SCHEMBL18660272 | 0.91 | F10 (0.62) | F10F2SLC29A1PDE4APDE4B | |
| SCHEMBL18040318 | 0.90 | F10 (0.61) | F10F2SLC29A1PDE4APDE4B | |
| SCHEMBL17572367 | 0.90 | F10 (0.61) | F10F2SLC29A1PDE4APDE4B | |
| SCHEMBL18040316 | 0.90 | F10 (0.61) | F10F2SLC29A1PDE4APDE4B | |
| SCHEMBL18058755 | 0.90 | F10 (0.61) | F10F2SLC29A1PDE4APDE4B | |
| SCHEMBL18410325 | 0.90 | F10 (0.60) | F10F2SLC29A1PDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117659011-A | New method for synthesizing apixaban | 华东理工大学 | 2024-03-08 | — | — | CN | claimed |
| CN-115385910-B | Preparation method of apixaban intermediate | 山东信谊制药有限公司 | 2022-12-30 | — | — | CN | claimed |
| CN-115385910-A | Preparation method of apixaban intermediate | 山东信谊制药有限公司 | 2022-11-25 | — | — | CN | claimed |
| EP-3894407-B1 | PROCESS FOR PREPARING APIXABAN | KRKA D D NOVO MESTO (SI) | 2025-07-02 | — | — | EP | disclosed |
| EP-4441042-A1 | 5-PYRIMIDINECARBOXAMIDE DERIVATIVES AND METHODS OF USING THE SAME | Rgenta Therapeutics, Inc. (US) | 2024-10-09 | — | — | EP | disclosed |
| CN-117720456-A | New method for synthesizing apixaban intermediate 3, 3-dichloro-1- (4-substituted phenyl) piperidine-2-ketone | 华东理工大学 | 2024-03-19 | — | — | CN | disclosed |
| CN-116253675-B | Synthesis method of N-substituted-2-piperidone | 山东信谊制药有限公司 | 2023-07-25 | — | — | CN | disclosed |
| CN-116253675-A | Synthesis method of N-substituted-2-piperidone | 山东信谊制药有限公司 | 2023-06-13 | — | — | CN | disclosed |
| WO-2023102231-A1 | 5-PYRIMIDINECARBOXAMIDE DERIVATIVES AND METHODS OF USING THE SAME | RGENTA THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| CN-115385910-B | Preparation method of apixaban intermediate | 山东信谊制药有限公司 | 2022-12-30 | — | — | CN | disclosed |
| CN-115385910-A | Preparation method of apixaban intermediate | 山东信谊制药有限公司 | 2022-11-25 | — | — | CN | disclosed |
| US-6995172-B2 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-02-07 | — | — | US | disclosed |
| US-6989391-B2 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS-SQUIBB PHARMA COMPANY (US) | 2006-01-24 | — | — | US | disclosed |
| US-20050267097-A1 | blood coagulation factor (trypsin-like serine protease enzymes) inhibitor; 3-(4-methoxy-phenyl)-5-[4-(2-oxo-2H-pyridin-1-yl)-phenyl]-3,5,6,7-tetrahydro-[1,2,3]triazolo4,5-c]pyridin-4-one; anticoagulant; cardiovascular thromboembolic disorder transient ischemic attack, stroke, atherosclerosis | BRISTOL-MYERS SQUIBB COMPANY | 2005-12-01 | — | — | US | disclosed |
| US-20050261287-A1 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-11-24 | — | — | US | disclosed |
| US-6967208-B2 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-11-22 | — | — | US | disclosed |
| US-20050171085-A1 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-08-04 | — | — | US | disclosed |
| US-20050124602-A1 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-06-09 | — | — | US | disclosed |
| US-20040220174-A1 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-04 | — | — | US | disclosed |
| US-20030191115-A1 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261287-A1 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | F12, F2, CPB1 | F10 45/4885F2 2/4885SLC29A1 3202/4885 |
| US-20040220174-A1 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | PEPD, PRSS1, CPB1 | F10 43/4885F2 4/4885SLC29A1 3160/4885 |
| US-20050124602-A1 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | F12, F2, CPB1 | F10 43/4885F2 2/4885SLC29A1 3302/4885 |
| US-20050267097-A1 | blood coagulation factor (trypsin-like serine protease enzymes) inhibitor; 3-(4-methoxy-phenyl)-5-[4-(2-oxo-2H-pyridin-1-yl)-phenyl]-3,5,6,7-tetrahydro-[1,2,3]triazolo4,5-c]pyridin-4-one; anticoagulant; cardiovascular thromboembolic disorder transient ischemic attack, stroke, atherosclerosis | PLAT, F2, TFPI | F10 62/4885F2 2/4885SLC29A1 4371/4885 |
| US-20050171085-A1 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | F12, F2, CPB1 | F10 45/4885F2 2/4885SLC29A1 3202/4885 |
| US-20030191115-A1 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | PEPD, HABP2, CPB1 | F10 33/4885F2 13/4885SLC29A1 2219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.